Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2023 | Tumor phenotype associated with patient survival in a pan-cancer prospective study

João Alessi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines his prospective study to identify independent sources of variation in tumor immune microenvironments (TIMEs) in different tumor types and their interaction with genomic alterations and patient survival. ImmunePROFILE was used to quantify tumor and immune cells and TIME variation identified; distinct phenotypes were associated with genomic alterations. Tumors with mutations in the Wnt/β-catenin pathways were associated with increased overall survival, whilst tumors with PD-L1+ cells proximal to tumor cells were associated with reduced overall survival. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.